Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07694440
Recruiting Phase 2

A Study of MZE782 in Adults With PKU

NCT07694440 · tracked via the Priya Life Science France tracker
Sponsor
Maze Therapeutics
Phase
Phase 2
Started
2026-06-23
Last updated
2026-10-23

Condition(s) studied

Phenylketonuria (PKU)

Investigational drug(s) / intervention(s)

MZE782PlaceboMZE782

MZE782: Tablet, Low Dose

Placebo: Tablet

MZE782: Tablet, High Dose

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Key Inclusion Criteria: * Males and females 18 to 75 years old * Confirmed diagnosis of PKU * Willing and able to keep diet and protein intake consistent during the study * For some study groups, is willing and able to stop certain PKU medications before starting study treatment * For some study groups, may need to meet additional blood phenylalanine level or background-treatment requirements * Meets minimum blood phenylalanine level requirements for study group Key Exclusion Criteria: * Is pregnant, breastfeeding, or planning to become pregnant or conceive a child during the study * Medical conditions or abnormal test results that could make participation unsafe or make it difficult to complete study procedures or interpret study results * Has recently received another investigational drug * Is unable to swallow tablets or tolerate oral medication Other inclusion/exclusion criteria defined in protocol apply.

Primary outcome measure(s)

  • Safety and tolerability based on incidence of adverse events (AEs) — Week 0 to Week 17
  • For Cohorts 1A and 1B: Absolute change in plasma Phe levels from Baseline to the mean of plasma Phe levels — Baseline and Weeks 2, 3, and 4

Trial sites (9)

FacilityCityRegionStatus
UCSF Benioff Children's Hospital Oakland Oakland California Recruiting
Stanford University Clinical and Translational Research Unit Palo Alto California Recruiting
Ann and Robert H. Lurie Children's Hospital of Chicago Chicago Illinois Recruiting
Indiana University School of Medicine Indianapolis Indiana Recruiting
University of Kentucky Medical Center Lexington Kentucky Recruiting
Clinic for Special Children Gordonville Pennsylvania Recruiting
University of Tennessee Health Science Center Le Bonheur Children's Hospital Memphis Tennessee Recruiting
CHRU Hôpitaux de Tours - Hôpital Bretonneau Tours France Recruiting
University College Hospital London United Kingdom Recruiting

More Maze Therapeutics trials in France

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease Recruiting

Other trials for the same condition

Multiomics Approach in Adult Patients With Phenylketonuria Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07694440 on ClinicalTrials.gov ↗ ← All trials in France